Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interview: New EFPIA President On The Future Of Innovation

Executive Summary

Jean-Christophe Tellier, the new president of EFPIA, tells the Pink Sheet why "connected health care" is the key to the future of innovation, how stakeholders should work collaboratively to address the affordability of new therapies, and why Brexit must not lead to fragmentation of the health care network in Europe. 

You may also be interested in...

UK Pharma Decries Govt's Latest No-Deal Brexit Planning

The provision of “express” freight capacity for medicines that need to be delivered urgently is among the latest proposals from the UK government to help cope with supply disruptions in the event of a no-deal Brexit. But the biopharmaceutical industry says some of the proposals are too short notice and will place additional burdens on companies.

New IMI Funding For EU Research Into ATMPs, Health Outcomes & Drug Info

Projects on T cells and advanced therapy medicinal products for rare diseases, patient reported outcomes in cancer clinical trials, and improvements to patient drug information are among the latest topics to be offered funding under Europe’s Innovative Medicines Initiative.

EFPIA On How To Make Cross-Country Collaborations Work

Cross-country collaboration on pricing and reimbursement will only work if they are based on certain overarching principles, says the European Federation of Pharmaceutical Industries and Associations.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts